intellectual property policy on pharmaceutical products: a view in the beginning of the 2000 decade - doi: 10.3395/reciis.v2i2.191en
Clicks: 235
ID: 229433
2009
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
235 views
15 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #6 of 8 articles by views in international journal of multiphase flow
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This paper aims at an analysis of the intellectual property policy in the health field by emphasizing the program of production and distribution of antiretrovirals and the generic drugs market, also reviewing the process of articulation and implementation of the intellectual property policy in this sector. From a methodological viewpoint, the paper favors the analysis of data related to the structuring of the pharmaceutical products market and of impacts both from the new institutionality and the intellectual property policies developed by the Ministry of Health in the first half of the 2000’s decade.
| Reference Key |
carvalho2009reciisintellectual
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Sergio M Paulino de Carvalho;Sergio Salles-Filho;Antonio Marcio Buainain;Maria Beatriz Bonacelli;Marcos Paulo Fuck |
| Journal | international journal of multiphase flow |
| Year | 2009 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.